Zhiyun Yang, Yingying Ge and Rui Zuo et al CVIA. 2025. Vol. 10(1). DOI: 10.15212/CVIA.2025.0014
Abstract
Asthma and cardiovascular diseases (CVDs) are intricately linked, because of their widespread prevalence and shared pathophysiological processes. People who have experienced overlapping asthma exacerbation, persistent asthma, or asthma-chronic obstructive pulmonary disease (COPD) face elevated CVD morbidity and mortality risks. These risks are exacerbated in cases of type 2 asthma, a common phenotype of severe asthma leading to accelerated CVD progression. However, type 2 inflammation also exhibits protective effects against CVDs. This review is aimed at exploring the dual role of type 2 inflammation in CVDs, emphasizing its detrimental effects (e.g., exacerbating atherosclerosis) and protective mechanisms (e.g., release of atheroprotective cytokines such as IL-5 and IL-13). Furthermore, it examines the therapeutic potential of anti-asthma medications targeting type 2 inflammation to mitigate CVD progression.